GREENWICH, Conn., Oct. 18, 2012 /CNW/ - Mederi Therapeutics Inc. today announced the signing of an exclusive agreement with Farouq, Maamoun, Tamer & Co., for distribution of its minimally invasive therapies in the Kingdom of Saudi Arabia. Mederi manufactures the Stretta System for treatment of Gastroesophageal Reflux Disease (GERD), and the Secca System for Bowel Incontinence or Bowel Control Disorder (BCD).
"As a result of a very successful physician training workshop, in which all patients treated with Stretta and Secca showed complete elimination of their symptoms or marked improvement, Tamer is delighted to represent Mederi in the KSA. The reaction of the physicians and patients to these treatments has been tremendously enthusiastic," said Mr. Talaat El-Alfi, Managing Director – Medical Division, of the Tamer Group.
The Stretta Physician Decides to Become the Stretta Patient
"I was so impressed with the data on Stretta and the treatments I performed that I decided to have Stretta performed on me," said Professor Mohammad Q. from Riyadh, KSA. "I have suffered with symptoms of GERD for many years. Shortly after my Stretta procedure, I had remarkable relief of GERD symptoms." Professor Q. continued, "I couldn't be more pleased with my own outcome, and especially with the outcomes of the patients we treated."
Milestone Shows Rapid and Widespread International Adoption of Stretta and Secca
"The addition of KSA brings the number of countries where the new Stretta and Secca are available to more than 35," stated Will Rutan, CEO of Mederi. "We are very pleased with the rapid and widespread adoption of the second generation Stretta and Secca systems," said Mr. Rutan.
Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat digestive diseases. Stretta for GERD, and Secca for Bowel Incontinence, are outpatient treatments that deliver radiofrequency energy to the sphincter muscles at either end of the digestive system. These therapies bridge the gap between conservative or drug therapy and invasive surgery or implants – offering effective and less complicated alternatives. Stretta and Secca provide durable relief to symptoms and are strongly backed by numerous clinical studies showing safety and long-term effectiveness. Mederi is located in Greenwich, Connecticut.
Contact: Sheila Doyle, 203-930-9980, email@example.com.
SOURCE: Mederi Therapeutics Inc
For further information: